58119-51-0

Basic information

• Product Name: 4-[4-(trifluoromethoxy)phenoxy]aniline
• Synonyms: 4-[4-(trifluoromethoxy)phenoxy]aniline;Benzenamine, 4-[4-(trifluoromethoxy)phenoxy]-;4-(4-(Trifluoromethoxy)Phenoxy)Aniline(WX602132)
• CAS NO: 58119-51-0
• Molecular Formula: C₁₃H₁₀F₃NO₂
• Molecular Weight: 269.2192096
• Mol File: 58119-51-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[4-(trifluoromethoxy)phenoxy]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(trifluoromethoxy)phenoxy]aniline(58119-51-0)
• EPA Substance Registry System: 4-[4-(trifluoromethoxy)phenoxy]aniline(58119-51-0)

Safety Data

• Hazardous Substances Data: 58119-51-0(Hazardous Substances Data)

Upstream product

• 74030-44-7 1-nitro-4-(4-(trifluoromethoxy)phenoxy)benzene 
• 828-27-3 4-Trifluoromethoxyphenol 
• 350-46-9 4-Fluoronitrobenzene 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 361547-21-9 dithiocarbonic acid O-ethyl ester S-(4-(4-trifluoromethoxyphenoxy)phenyl) ester 
• 220616-47-7 4-(4'-trifluoromethoxyphenoxy)-benzenethiol 
• 361547-22-0 methyl (4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)acetate 
• 396131-74-1 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide 
• 396131-78-5 2-hydroxy-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide 
• 396131-75-2 2-hydroxy-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)propane-1-sulfonic acid dimethyl amide 
• 396131-79-6 2-hydroxyamino-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)propane-1-sulfonic acid dimethyl amide 
• 74030-45-8 4-(4-(trifluoromethoxy)phenoxy)phenol 
• 873203-37-3 1-iodo-4-(4-(trifluoromethoxy)-phenoxy)benzene 
• 1426337-32-7 4,4,5,5-tetramethyl-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)-1,3,2-dioxaborolane 
• 1426336-80-2 (S)-6-((1-amino-1-oxopropan-2-yl)amino)-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)pyrimidine-4-carboxamide 
• 1438233-95-4 (E)-N-(7-chloro-1-ethylquinolin-4(1H)-ylidene)-4-(4-(trifluoromethoxy)phenoxy)aniline trifluoromethanesulfonate 
• 1366234-50-5 C₁₇H₁₃F₃N₄O₂ 
• 1366234-43-6 C₁₇H₁₃F₃N₄O₂ 

Relevant articles and documents

Novel bicyclic nitroimidazole carbamate compounds, process for preparation thereof and pharmaceutical composition for preventing or treating tuberculosis containing the same as an active ingredient

A bicyclic nitroimidazole carbamate compound represented by chemical formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition for preventing or treating tuberculosis disease containing the same as an active ingredient. Chemical Formula 1. In Chemical Formula 1, R. 1 And R2 Are as defined in the description of the invention. The bicyclic nitroimidazole carbamate compounds of the present invention exhibit excellent inhibitory effects on vitality and non-active tuberculosis. The compounds can be useful in the treatment of tuberculosis.

Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipop

PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS

The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

Quinolin-4(1 H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria

We present a novel series of quinolin-4(1H)-imines as dual-stage antiplasmodials, several-fold more active than primaquine in vitro against Plasmodium berghei liver stage. Among those, compounds 5g and 5k presented low nanomolar IC50 values. The compounds are metabolically stable and modulate several drug targets. These results emphasize the value of quinolin-4(1H)-imines as a new chemotype and their suitable properties for further drug development.

PYRIMIDINES AS SODIUM CHANNEL BLOCKERS

The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

PAI-1 INHIBITOR

The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; wherein: R1 represents a C6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0

N-Phenyloxamide derivatives

A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R1 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, cyano group, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group and a C1-6 alkylsulfanyl group, R2 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, hydroxy group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group, a C1-6 alkylsulfanyl group and phenyl group, X represents a single bond or oxygen atom, Z represents a phenylene group or a substituted phenylene group, m represents 0 or 1.

Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors

A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1′ substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a.highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.